Reexamination of the TEMPO Study.
Shults
Clifford W
CW
D000975:Antioxidants / Q000494:pharmacology / Q000627:therapeutic use; D000978:Antiparkinson Agents / Q000494:pharmacology / Q000627:therapeutic use; D016477:Artifacts; D004347:Drug Interactions; D006801:Humans; D007189:Indans / Q000494:pharmacology* / Q000627:therapeutic use; D008996:Monoamine Oxidase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D018696:Neuroprotective Agents / Q000494:pharmacology / Q000627:therapeutic use; D010300:Parkinson Disease / Q000188:drug therapy* / Q000503:physiopathology; D018579:Patient Selection; D016032:Randomized Controlled Trials as Topic / Q000592:standards / Q000706:statistics & numerical data; D012107:Research Design / Q000592:standards; D012642:Selegiline / Q000627:therapeutic use; D016896:Treatment Outcome
D000975:Antioxidants; D000978:Antiparkinson Agents; D007189:Indans; D008996:Monoamine Oxidase Inhibitors; D018696:Neuroprotective Agents; C031967:rasagiline; D012642:Selegiline